BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 11340253)

  • 21. Acute myeloid leukemia M2 and t(8;21)(q22;q22) with an unusual phenotype: myeloperoxidase (+), CD13 (-), CD14 (-), and CD33(-).
    García Vela JA; Martin M; Delgado I; García Alonso L; Monteserin MC; Benito L; Somolinos N; Oña F
    Ann Hematol; 1999 May; 78(5):237-40. PubMed ID: 10391105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.
    Lee SH; Lee MH; Lee JH; Min YH; Lee KH; Cheong JW; Lee J; Park KW; Kang JH; Kim K; Kim WS; Jung CW; Choi SJ; Lee JH; Park K
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):122-8. PubMed ID: 15682073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study.
    Laczika K; Novak M; Hilgarth B; Mitterbauer M; Mitterbauer G; Scheidel-Petrovic A; Scholten C; Thalhammer-Scherrer R; Brugger S; Keil F; Schwarzinger I; Haas OA; Lechner K; Jaeger U
    J Clin Oncol; 1998 Apr; 16(4):1519-25. PubMed ID: 9552061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discordant expression of myeloid antigens and myeloperoxidase in a case of t(8;21) positive AML expressing CD7.
    Hirai K; Torimoto Y; Moriichi K; Sato K; Ohnishi K; Taya N; Kohgo Y
    Int J Hematol; 1999 Jul; 70(1):30-5. PubMed ID: 10446492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy-related acute leukemia with mixed phenotype and t(9;22)(q32;q11.2): a case report and review of the literature.
    Cho JH; Hur M; Moon HW; Yun YM; Ko YS; Kim WS; Lee MH
    Hum Pathol; 2012 Apr; 43(4):605-9. PubMed ID: 22036054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
    Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [CD56-positive acute myeloid leukemia patient with t(16;21)(p11.2;q22) relapsing with isolated pericardial effusion after HLA-haploidentical peripheral blood stem cell transplantation].
    Yamaguchi T; Katsuragi T; Tsukada J
    Rinsho Ketsueki; 2019; 60(12):1669-1671. PubMed ID: 31902819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Localized relapse in bone marrow in a posttransplantation patient with t(6;9) acute myeloid leukemia.
    Maeda T; Kosugi S; Ujiie H; Osumi K; Fukui T; Yoshida H; Kashiwagi H; Ishikawa J; Tomiyama Y; Matsuzawa Y
    Int J Hematol; 2003 Jun; 77(5):522-5. PubMed ID: 12841393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A child case of CD34+, CD33-, HLA-DR-, CD7+, CD56+ stem cell leukemia with thymic involvement.
    Nagata T; Higashigawa M; Nagai M; Zhang XL; Azuma E; Komada Y; Sakurai M
    Leuk Res; 1996; 20(11-12):983-5. PubMed ID: 9009257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
    J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute myeloid leukemia with t(16;21)(q24;q22) and eosinophilia: case report and review of the literature.
    Park IJ; Park JE; Kim HJ; Jung HJ; Lee WG; Cho SR
    Cancer Genet Cytogenet; 2010 Jan; 196(1):105-8. PubMed ID: 19963144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
    Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
    Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The detection of residual acute lymphoblastic leukemia cells with immunologic methods and polymerase chain reaction: a comparative study.
    Campana D; Yokota S; Coustan-Smith E; Hansen-Hagge TE; Janossy G; Bartram CR
    Leukemia; 1990 Sep; 4(9):609-14. PubMed ID: 1975635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring of minimal residual leukemia in patients with MLL-AF9 positive acute myeloid leukemia by RT-PCR.
    Mitterbauer G; Zimmer C; Fonatsch C; Haas O; Thalhammer-Scherrer R; Schwarzinger I; Kalhs P; Jaeger U; Lechner K; Mannhalter C
    Leukemia; 1999 Oct; 13(10):1519-24. PubMed ID: 10516752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
    Locatelli F; Pession A; Bonetti F; Maserati E; Prete L; Pedrazzoli P; Zecca M; Prete A; Paolucci P; Cazzola M
    Leukemia; 1994 May; 8(5):844-9. PubMed ID: 8182940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
    Yin CC; Cortes J; Barkoh B; Hayes K; Kantarjian H; Jones D
    Cancer; 2006 Apr; 106(8):1730-8. PubMed ID: 16532439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Acute monoblastic leukemia (M5a) with dysmegakaryocytopoiesis associated with t(16;21) (p11;q22)].
    Satoh K; Miura I; Chubachi A; Ohtani H; Hirokawa M; Niitsu H; Miura AB
    Rinsho Ketsueki; 1994 Feb; 35(2):160-4. PubMed ID: 8139114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of minimal residual disease (MRD) after bone marrow transplantation (BMT) by multi-parameter flow cytometry (MPFC).
    Nagler A; Condiotti R; Rabinowitz R; Schlesinger M; Nguyen M; Terstappen LW
    Med Oncol; 1999 Sep; 16(3):177-87. PubMed ID: 10523797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics and prognostic factors of acute myeloid leukemia with t (8; 21) (q22; q22).
    Lai YY; Qiu JY; Jiang B; Lu XJ; Huang XJ; Zhang Y; Liu YR; Shi HL; Lu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):733-40. PubMed ID: 16277833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
    Zittoun RA; Mandelli F; Willemze R; de Witte T; Labar B; Resegotti L; Leoni F; Damasio E; Visani G; Papa G
    N Engl J Med; 1995 Jan; 332(4):217-23. PubMed ID: 7808487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.